Healthcare

In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) highlighted increasing biosimilar and generic competition, pricing pressure, and the strengthening of the US dollar as key challenges for the company in fiscal 2019.

Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.

Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.

In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.

Devon Energy (DVN) continues to trade below its short-term (50-day) moving average.